Neuroene Therapeutics seeks to optimize vitamin K analogues that could improve seizure control in patients with drug-resistant epilepsy.
The C-TIME program can be successfully implemented in the community and is associated with improved outcomes in adults with epilepsy and related mental health conditions.
Living with adult-onset epilepsy can challenge a person's sense of self and trust in their body, resulting in the adoption of various strategies to manage the threat to their identity
CURE is heading to Disneyland for Epilepsy Awareness Day from November 5 – 7, 2018!
Seizure outcome of VNS may be influenced by metabolic connectivity, which can be obtained from preoperative PET imaging.
SUDEP
A new high-tech bracelet, developed by scientists from the Netherlands, detects 85 percent of all severe night-time epilepsy seizures. That is a much better score than any other technology currently available.
Aquestive Therapeutics announced the completion of a study demonstrating that its investigational diazepam buccal film (DBF) provides comparable bioavailability whether administered between seizures or during and shortly after seizures in adult patients with poorly controlled tonic-clonic seizures or focal seizures with impaired awareness.
The perceived stigma of epilepsy was greater than stigma in human immunodeficiency virus/acquired immune deficiency syndrome in Accra.
Pediatric Epilepsy
The FDA has approved abbreviated new drug applications to immediately market a generic version of clobazam (Onfi) (Lundbeck) tablets, CIV, 10 mg and 20 mg, and clobazam oral suspension, CIV, 2.5 mg/mL, for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older.
